Morphometric Markers of the Effectiveness of Micropulse Cyclophotocoagulation

NCT07592923 | Recruiting

• 1 other identifier: 193
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

This prospective study aims to evaluate morphometric markers of treatment response following micropulse transscleral cyclophotocoagulation (MP-CPC) in patients with glaucoma. The study will assess changes in choroidal thickness and the choroidal vascularity index (CVI) measured by optical coherence tomography (OCT) before treatment, 3-7 days after the procedure, and 1 month postoperatively. Intraocular pressure (IOP) will be measured at the same time points. The correlation between changes in choroidal thickness, the choroidal vascularity index (CVI) and IOP reduction will be analyzed. Additionally, the study seeks to determine the minimal baseline choroidal thickness associated with a clinically significant hypotensive effect after MP-CPC.

Conditions

Glaucoma

Keywords

micropulse laser; glaucoma

Outcome Measures

Primary Outcomes (1)

• Changes in intraocular pressure measurements between baseline and postoperative follow-up visits

  Baseline (pre-operative condition) and post operative intraocular pressure will be measured

  Day 1, Day 3, Week 1, Week 2, Month 1

Secondary Outcomes (1)

• Rate of post surgical complications

  Day 1, Day 3, Week 1, Week 2, Months 1

Study Arms (2)

MicroPulse transscleral cyclophotocoagulation group

EXPERIMENTAL

Participants in this group will undergo MicroPulse transscleral cyclophotocoagulation for glaucoma. The procedure will be performed using a laser power of 2500 mW, with a treatment duration of 100-120 seconds per hemifield and 5-6 sweeps per hemifield.

Procedure: MicroPulse transscleral cyclophotocoagulation

Conventional transscleral cyclophotocoagulation group

EXPERIMENTAL

Participants in this group will undergo conventional transscleral cyclophotocoagulation for glaucoma. The procedure will be performed using a laser power of 1.4-2.3 W, with an exposure duration of 1.4-1.8 seconds per coagulation spot.

Procedure: Conventional transscleral cyclophotocoagulation

Interventions

MicroPulse transscleral cyclophotocoagulation PROCEDURE

MicroPulse transscleral cyclophotocoagulation will be performed as a laser procedure for the treatment of glaucoma. Laser treatment will be applied transsclerally over the ciliary body using a power of 2500 mW. The treatment duration will be 100-120 seconds per hemifield, with 5-6 sweeps per hemifield.

MicroPulse transscleral cyclophotocoagulation group

Conventional transscleral cyclophotocoagulation PROCEDURE

Conventional transscleral cyclophotocoagulation will be performed as a laser procedure for the treatment of glaucoma. Laser treatment will be applied transsclerally over the ciliary body using a power of 1.4-2.3 W, with an exposure duration of 1.4-1.8 seconds per coagulation spot.

Conventional transscleral cyclophotocoagulation group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Decision to treat by MP-CPC Laser
• Patients diagnosed with Glaucoma
• Patients aged 18 years old and above
• Glaucoma that is inadequately controlled on medical therapy

You may not qualify if:

• Patients age less than 18 years
• Patients unable or unwilling to provide informed consent to participate in the study
• Patients potentially unavailable for follow up visits
• Patients with significant scleral thinning
• Patients with ocular infection, inflammation or intraocular surgery in the study eye 2 months prior to enrollment in the study
• Albino patients that have no iris pigmentation

Sponsors & Collaborators

• Kazakh Eye Research Institute: lead

Study Sites (1)

Kazakh Eye Research Institute

Almaty, 050012, Kazakhstan

RECRUITING

MeSH Terms

Conditions

Glaucoma

Condition Hierarchy (Ancestors)

Ocular Hypertension; Eye Diseases

Study Officials

• Assiya Shaikenova, MD

  Kazakh Eye Research Institute

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Assiya Shaikenova, MD

CONTACT

+77055689966; shaikenova93@mail.ru

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 12, 2026
• First Posted: May 18, 2026
• Study Start: May 18, 2026
• Primary Completion (Estimated): August 18, 2026
• Study Completion (Estimated): August 18, 2026
• Last Updated: May 18, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

KA (1)